Omics Global Solutions
Omics Global Solutions (OGS) is a biotechnology company based in Puerto Rico, focused on developing and commercializing products related to OMICS sciences, including proteomics. The company aims to impact patients and medical professionals positively through innovative projects, such as the development of diagnostic tests like INNOVATIO ND2™ for diabetic nephropathy. With a mission to develop clinical prognostic products based on scientific models and a vision to be a leading biotech company in LATAM and the US by 2030, Omics is committed to high-quality standards and bringing science to the community.
Industries
Nr. of Employees
small (1-50)
Omics Global Solutions
Río Piedras, Salta, Argentina, South America
Products
ELISA assay for diabetic kidney disease diagnosis and risk stratification
An ELISA-format in vitro diagnostic assay that provides both diagnostic and prognostic measurements to identify risk of developing diabetic nephropathy in patients with type 2 diabetes.
INNOVATIO ND2
The first ELISA test in the world for the diagnosis and risk identification of developing Diabetic Nephropathy in type 2 diabetes patients, providing dual diagnostic and prognostic risk measurements.
ELISA assay for diabetic kidney disease diagnosis and risk stratification
An ELISA-format in vitro diagnostic assay that provides both diagnostic and prognostic measurements to identify risk of developing diabetic nephropathy in patients with type 2 diabetes.
INNOVATIO ND2
The first ELISA test in the world for the diagnosis and risk identification of developing Diabetic Nephropathy in type 2 diabetes patients, providing dual diagnostic and prognostic risk measurements.
Services
Development of biomarker-based assays and execution of technical transfer strategies to enable commercial and clinical laboratory deployment.
Establishing regional distributor and clinical laboratory partnerships to introduce diagnostic assays into Latin American and U.S. markets.
Data analysis and bioinformatics applied to proteomics datasets to support precision-medicine research and interpretation.
Development of biomarker-based assays and execution of technical transfer strategies to enable commercial and clinical laboratory deployment.
Establishing regional distributor and clinical laboratory partnerships to introduce diagnostic assays into Latin American and U.S. markets.
Data analysis and bioinformatics applied to proteomics datasets to support precision-medicine research and interpretation.
Expertise Areas
- Biomarker discovery and validation
- Proteomics and clinical proteomics
- In vitro diagnostic assay development (ELISA)
- Antibody generation for diagnostics
Key Technologies
- Enzyme-linked immunosorbent assay (ELISA)
- Proteomics
- Antibody-based assays
- Biomarker assays
News & Updates
Chosen as one of the 14 PyMES INNOVADORAS Grant Program from Puerto Rico Development Company (2018)
Participation in the 7th Generation of Parallel 18 acceleration program
INNOVATIO ND2™ received ISO certification for clinical diagnostic use (2019)
Selected for Puerto Rico Development Company Grant Program
Chosen as one of the 14 innovative PyMES in Puerto Rico in 2018.
Participation in Parallel 18 acceleration program
Chosen as one of the 14 PyMES INNOVADORAS Grant Program from Puerto Rico Development Company (2018)
Participation in the 7th Generation of Parallel 18 acceleration program
INNOVATIO ND2™ received ISO certification for clinical diagnostic use (2019)
Selected for Puerto Rico Development Company Grant Program
Chosen as one of the 14 innovative PyMES in Puerto Rico in 2018.